MPLT — MapLight Therapeutics, Inc. Common Stock Stock Price, Chart & AI Report

Positive Jan 9, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics announced that its Phase 2 ZEPHYR trial for ML-007C-MA (schizophrenia treatment) and Phase 2 IRIS trial for ML-004 (autism spectrum disorder) are progressing ahead of schedule, with topline results now expected in Q3 2026. The company cited accelerated enrollment pace and disciplined execution as drivers of the timeline acceleration.

MPLT Phase 2 clinical trials ZEPHYR trial IRIS trial schizophrenia autism spectrum disorder topline results enrollment acceleration

Sentiment note

The company reported accelerated enrollment in its Phase 2 trials ahead of schedule, demonstrating strong execution and momentum in clinical development. The narrowed timing guidance to Q3 2026 for both ZEPHYR and IRIS trials indicates progress and operational efficiency, which are positive indicators for investors and stakeholders.

Positive Oct 29, 2025 • 13:06 UTC Benzinga • Globe Newswire

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

MapLight Therapeutics completed its initial public offering of 16,962,500 shares at $17.00 per share, raising $296.3 million. The company is a clinical-stage biopharmaceutical firm focused on central nervous system disorders, with a lead product candidate ML-007C-MA for schizophrenia and Alzheimer's disease psychosis.

MPLT IPO biopharmaceutical central nervous system schizophrenia Alzheimer's

Sentiment note

Successfully completed IPO, raised significant capital ($296.3M), trading on Nasdaq, advancing clinical-stage drug development for neurological disorders